Brief: Grifols Confirms 2025 Guidance
12/05/2025 16:45
May 12 (Reuters) - Grifols SA GRLS.MC: CONFIRMS 2025 GUIDANCE ON TRACK TO LAUNCH FIBRINOGEN IN EUROPE IN Q4’25 AND IN THE U.S. IN H1’26, FOLLOWING FDA APPROVAL EXPECTS TO SHARE GREATER DETAIL IN 2025 DUE TO IMPACT OF INFLATION REDUCTION ACT ON ITS FINANCIAL RESULTS Source text: ID:nCNMbPvmzD Further company coverage: GRLS.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Grifols SA
See all newsSpanish stocks - Factors to watch on June 24
Brief: Grifols Approves Reduction Of Up To 10% Of Its Share Capital
Brief: Grifols Launches Fibrinogen Concentrate For Acute Bleeding Episodes In The U.S.
Brief: Grifols' Egypt Unit Adds €180 Mln Of Additional Investment In Project
Spanish stocks - Factors to watch on June 12